Home research company Mannin GmbH implements CDD Vault IT platform to facilitate data management and collaboration

Mannin GmbH implements CDD Vault IT platform to facilitate data management and collaboration


LEIPZIG, Germany and SAN FRANCISCO, November 24, 2021 / PRNewswire / – Mannin GmbH, a biotechnology company specializing in the research and development of novel vascular therapies, today announced that it has implemented CDD Vault in its Leipzig laboratories. CDD Vault, a hosted chemistry and biology research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), will be used to manage all of the company’s research data and collaborative projects across all geographic areas.

Mannin has an established eye disease pipeline with a first-class drug for primary open-angle glaucoma. It also has a new drug candidate designed to restore normal fluid flow in the eye and reduce intraocular eye pressure (IOP), a leading cause of glaucoma. Using the same principles, Mannin is developing new therapies to treat a range of vascular diseases, including cystic kidney disease, pediatric glaucoma and inflammation.

CDD Vault is a hosted platform designed to manage drug discovery data, including small molecules and biologics, along with all associated experimental and contextual information. The platform incorporates fully integrated capabilities for activity and recording, inventory, visualization and a flexible electronic lab notebook. It also includes a documented RESTful API that allows organizations to integrate CDD Vault with other software tools.

“I am very happy with the implementation of CDD Vault at Mannin. I highly appreciate CDD Vault as a tool that offers not only a solution for a digital chemistry lab notebook, but also a database that combines chemical and biological data in a very powerful way, said Dr. Andreas Schoop, head of medicinal chemistry at Mannin. “This is particularly important since we have just opened our new medicinal chemistry laboratories in Leipzig, while most of the biology is carried out by our parent company in Toronto, Canada or by external CROs. CDD Vault will help us share data and collaborate more efficiently. “

“We are delighted that Mannin researchers chose CDD Vault because their new therapies have the potential to change the lives of millions of people around the world,” said Dr. Mariana Vaschetto, Head of EMEA operations at CDD, “Pharma, biotechnologies and academics through Europe are increasingly adopting CDD Vault as their primary research data management platform, and we are privileged to support them. “


Mannin GmbH is a biotechnology company with research laboratories in the BioCity in Leipzig. Mannin’s development activities focus on treatments for vascular disease by targeting the Angiopoietin-Tie2 signaling pathway. Mannin develops drugs based on small molecules and biologics as well as companion diagnostics (eg to detect glaucoma). In addition, Mannin researches and pursues new innovations and development opportunities.


CDD (www.collaborativedrug.com), the flagship product, “CDD Vault®”, is used to securely manage chemical registration, structure-activity relationships (SAR) and collaborations at scale. CDD Vault® is a hosted database solution for the secure management and sharing of biological and chemical data. It allows you to intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. Modules available in CDD Vault include Activity and Record, View, Inventory, and ELN.

Dr. Mariana Vaschetto
[email protected]

SOURCE Collaborative drug discovery